{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T03:02:14Z","timestamp":1761102134922},"reference-count":93,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1016\/j.clinthera.2015.02.009","type":"journal-article","created":{"date-parts":[[2015,4,6]],"date-time":"2015-04-06T07:54:49Z","timestamp":1428306889000},"page":"1092-1112","source":"Crossref","is-referenced-by-count":6,"title":["Finding Truth in a World Full of Spin: Myth-Busting in the Case of Sovaldi"],"prefix":"10.1016","volume":"37","author":[{"given":"Leora","family":"Schiff","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2015.02.009_bib1","unstructured":"Robert Weisman (June 1, 2014). Demand for expensive hepatitis C drug strains insurers: When \u2018miracle\u2019 cures, cost collide. In The Boston Globe. Retrieved on August 18, 2014 from http:\/\/www.bostonglobe.com\/business\/2014\/05\/31\/costly-new-hepatitis-treatments-curing-patients-but-straining-health-care-system-finances\/SmBE9NoUESxjfgphfqvXKL\/story.html."},{"key":"10.1016\/j.clinthera.2015.02.009_bib2","series-title":"Highlights of prescribing information [package insert]","year":"2013"},{"key":"10.1016\/j.clinthera.2015.02.009_bib3","first-page":"711","article-title":"Novel therapies for hepatitis C\u2014one pill fits all?","volume":"13","author":"Manns","year":"2014","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.clinthera.2015.02.009_bib4","unstructured":"AASLD\/IDSA\/IAS\u2013USA. Recommendations for Testing, Managing, and Treating Hepatitis C. Retrieved on August 19, 2014 from http:\/\/www.hcvguidelines.org. Revised August 11, 2014."},{"key":"10.1016\/j.clinthera.2015.02.009_bib5","unstructured":"Gilead Sciences, Inc (October 25, 2013). sofosbuvir for Treatment of Chronic Hepatitis C Infection: Antiviral Drugs Advisory Committee Meeting Briefing Document. NDA 204671."},{"key":"10.1016\/j.clinthera.2015.02.009_bib6","unstructured":"European Medicines Agency (February 5, 2014; updated August 26, 2014). Sovaldi: European Public Assessment Report (EPAR)\u2014Product Information."},{"key":"10.1016\/j.clinthera.2015.02.009_bib7","unstructured":"Rockstroh JK. Summary from AASLD 2014 for Hepatitis C. Conference Reports for NATAP, Boston, MA, November 7\u201311, 2014. Retrieved on December 26, 2014, from http:\/\/www.natap.org\/2014\/AASLD\/AASLD_93.htm."},{"issue":"suppl","key":"10.1016\/j.clinthera.2015.02.009_bib8","article-title":"Safety and efficacy of sofosbuvir-containing regimens for hepatitis C: real-world experience in a diverse, longitudinal observational cohort","volume":"60","author":"Jensen","year":"2014","journal-title":"Hepatology"},{"issue":"suppl","key":"10.1016\/j.clinthera.2015.02.009_bib9","article-title":"Evaluation of sofosbuvir and simeprevir-based regimens in the TRIO network: academic and community treatment of a real-world, heterogeneous population","volume":"60","author":"Dieterich","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.clinthera.2015.02.009_bib10","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1001\/jama.2013.109309","article-title":"sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial","volume":"310","author":"Osinusi","year":"2013","journal-title":"JAMA"},{"issue":"suppl","key":"10.1016\/j.clinthera.2015.02.009_bib11","article-title":"Safety, anti-viral efficacy and pharmacokinetics (PK) of sofosbuvir (SOF) in patients with severe renal impairment","volume":"60","author":"Gane","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.clinthera.2015.02.009_bib12","unstructured":"Food and Drug Administration, US Dept of Health and Human Services (October 10, 2014). FDA Approves First Combination Pill To Treat Hepatitis C. [FDA News Release] Retrieved on October 26, 2014, from http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm418365.htm."},{"key":"10.1016\/j.clinthera.2015.02.009_bib13","series-title":"Highlights of prescribing information [package insert]","year":"2014"},{"issue":"20","key":"10.1016\/j.clinthera.2015.02.009_bib14","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1056\/NEJMoa1402355","article-title":"Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis","volume":"370","author":"Kowdley","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2015.02.009_bib15","series-title":"Highlights of prescribing information [package insert]","year":"2014"},{"key":"10.1016\/j.clinthera.2015.02.009_bib16","series-title":"AbbVie Inc","article-title":"Highlights of prescribing information [package insert]","year":"2014"},{"key":"10.1016\/j.clinthera.2015.02.009_bib17","series-title":"The Comparative Clinical Effectiveness and Value of Novel Combination Therapies for the Treatment of Patients with Genotype 1 Chronic Hepatitis C Infection: A Technology Assessment Draft Report","author":"Tice","year":"2014"},{"key":"10.1016\/j.clinthera.2015.02.009_bib18","unstructured":"Pollack A. (October 10, 2014). Harvoni, a Hepatitis C Drug From Gilead, Wins F.D.A. Approval. In The New York Times. Retrieved on October 24, 2014, from http:\/\/www.nytimes.com\/2014\/10\/11\/business\/harvoni-a-hepatitis-c-drug-from-gilead-wins-fda-approval.html?_r=0."},{"key":"10.1016\/j.clinthera.2015.02.009_bib19","unstructured":"Edney A. (November 6, 2014). J&J Wins US Approval for Hepatitis C Combo With Gilead. In Bloomberg News. Retrieved on January 5, 2015, from http:\/\/www.bloomberg.com\/news\/2014-11-05\/j-j-wins-u-s-approval-for-hepatitis-c-combo-with-gilead.html."},{"key":"10.1016\/j.clinthera.2015.02.009_bib20","unstructured":"AbbVie (December 19, 2014). AbbVie Receives US FDA Approval of VIEKIRA PAK (Ombitasvir\/Paritaprevir\/Ritonavir Tablets; Dasabuvir Tablets) for the Treatment of Chronic Genotype 1 Hepatitis C. Retrieved on December 27, 2014, from http:\/\/abbvie.mediaroom.com\/2014-12-19-AbbVie-Receives-U-S-FDA-Approval-of-VIEKIRA-PAK-Ombitasvir-Paritaprevir-Ritonavir-Tablets-Dasabuvir-Tablets-for-the-Treatment-of-Chronic-Genotype-1-Hepatitis-C."},{"key":"10.1016\/j.clinthera.2015.02.009_bib21","unstructured":"Gane EJ, Highland RH, An D et al. High Efficacy of LDV\/SOF Regimens for 12 Weeks for Patients With HCV Genotype 3 or 6 Infection. Conference Reports for NATAP. Retrieved on December 26, 2014, from http:\/\/www.natap.org\/2014\/AASLD\/AASLD_27.htm."},{"issue":"suppl","key":"10.1016\/j.clinthera.2015.02.009_bib22","article-title":"Safety and efficacy of treatment with sofosbuvir+gs-5816\u00b1ribavirin for 8 or 12 weeks in treatment na\u00efve patients with genotype 1-6 HCV infection","volume":"60","author":"Tran","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.clinthera.2015.02.009_bib23","series-title":"Highlights of prescribing information [package insert]","year":"2008"},{"key":"10.1016\/j.clinthera.2015.02.009_bib24","series-title":"Highlights of prescribing information [package insert]. Reference ID: 3004561","year":"2011"},{"key":"10.1016\/j.clinthera.2015.02.009_bib25","doi-asserted-by":"crossref","first-page":"685","DOI":"10.18553\/jmcp.2011.17.9.685","article-title":"Formulary management of the protease inhibitors boceprevir and telaprevir for chronic hepatitis C virus","volume":"17","author":"Tungol","year":"2011","journal-title":"J Manag Care Pharm"},{"key":"10.1016\/j.clinthera.2015.02.009_bib26","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/apt.12342","article-title":"Adherence to assigned dosing regimen and sustained virological response among chronic hepatitis C genotype 1 patients treated with boceprevir plus peginterferon alfa-2b\/ribavirin","volume":"38","author":"Gordon","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2015.02.009_bib27","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1111\/j.1478-3231.2011.02461.x","article-title":"Adherence to treatment and quality of life during hepatitis C therapy: a prospective, real-life, observational study","volume":"31","author":"Marcellin","year":"2011","journal-title":"Liver Int"},{"key":"10.1016\/j.clinthera.2015.02.009_bib28","first-page":"653976","article-title":"Evaluation of the significance of pretreatment liver biopsy and baseline mental health disorder diagnosis on hepatitis c treatment completion rates at a Veterans Affairs Medical Center","volume":"2013","author":"Kluck","year":"2013","journal-title":"Hepat Res Treat"},{"key":"10.1016\/j.clinthera.2015.02.009_bib29","unstructured":"Gilead Sciences Policy Position (April 2014). Gilead\u2019s Efforts to Ensure Patient Access to Sovaldi for Chronic Hepatitis C. Foster City, Ca: Gilead Sciences, Inc"},{"key":"10.1016\/j.clinthera.2015.02.009_bib30","unstructured":"Smith M. (May 21, 2014). AHIP Blasts \u2018Unsustainable\u2019 Drug Costs. In MedPageToday. Retrieved on September 21, 2014, from http:\/\/www.medpagetoday.com\/InfectiousDisease\/Hepatitis\/45920."},{"key":"10.1016\/j.clinthera.2015.02.009_bib31","unstructured":"Langreth R. (March 3, 2014). Gilead CEO Becomes Billionaire on $84,000 Hepatitis Drug. In Bloomberg News. Retrieved on August 18, 2014, from http:\/\/www.bloomberg.com\/news\/2014-03-03\/gilead-ceo-becomes-billionaire-on-84-000-hepatitis-drug.html."},{"key":"10.1016\/j.clinthera.2015.02.009_bib32","series-title":"(April 15, 2014) The Comparative Clinical Effectiveness and Value of Simeprevir and sofosbuvir in the Treatment of Chronic Hepatitis C Infection: A Technology Assessment Final Report","author":"Tice","year":"2014"},{"key":"10.1016\/j.clinthera.2015.02.009_bib33","doi-asserted-by":"crossref","unstructured":"Garde D. (December 19, 2014). Updated: AbbVie wins blockbuster hep C approval, starts wheeling and dealing on price. In FierceBiotech. Retrieved on December 24, 2014, from http:\/\/www.fiercebiotech.com\/story\/abbvies-blockbuster-hep-c-approval-puts-it-toe-toe-gilead\/2014-12-19.","DOI":"10.1044\/leader.PPL.19122014.20"},{"key":"10.1016\/j.clinthera.2015.02.009_bib34","unstructured":"Edney A, Chen C. (December 19, 2014). AbbVie Prices Hepatitis C Drug 12% Below Gilead Rival. In Bloomberg News. Retrieved on December 24, 2014, from http:\/\/www.bloomberg.com\/news\/2014-12-19\/abbvie-wins-u-s-approval-to-sell-new-hep-c-competitor.html."},{"key":"10.1016\/j.clinthera.2015.02.009_bib35","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/ajg.2012.48","volume":"107","author":"Yee","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.clinthera.2015.02.009_bib36","doi-asserted-by":"crossref","first-page":"6","DOI":"10.5501\/wjv.v2.i1.6","article-title":"Hepatitis C virus resistance to new specifically-targeted antiviral therapy: a public health perspective","volume":"2","author":"Salvatierra","year":"2013","journal-title":"World J Virol"},{"key":"10.1016\/j.clinthera.2015.02.009_bib37","doi-asserted-by":"crossref","unstructured":"Ghany MG, Nelson DR, Strader DB, et al. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011;54:1433\u20131444.","DOI":"10.1002\/hep.24641"},{"key":"10.1016\/j.clinthera.2015.02.009_bib38","article-title":"EASL Recommendations on Treatment of Hepatitis C","author":"Pawlotsky","year":"2014","journal-title":"European Association for the Study of the Liver"},{"key":"10.1016\/j.clinthera.2015.02.009_bib39","unstructured":"World Health Organization (April 2014). Guidelines for the screening, care and treatment of persons with hepatitis infection. Geneva, Switzerland, WHO. NLM classification WC 536"},{"issue":"suppl","key":"10.1016\/j.clinthera.2015.02.009_bib40","article-title":"The impact of liver disease on the health-related quality of life","volume":"60","author":"Cortesi","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.clinthera.2015.02.009_bib41","unstructured":"Decision Resources (August 19, 2014). Nearly Half of Surveyed Specialists Expect to Prescribe Gilead\u2019s sofosbuvir\/Ledipasvir Regimen Near-Term for Hepatitis C Infections. Retrieved on September 21, 2014, from http:\/\/www.prnewswire.com\/news-releases\/nearly-half-of-surveyed-specialists-expect-to-prescribe-gileads-sofosbuvirledipasvir-regimen-near-term-for-hepatitis-c-infections-271839651.html."},{"issue":"suppl","key":"10.1016\/j.clinthera.2015.02.009_bib42","article-title":"sofosbuvir-containing regimens for chronic hepatitis C (CHC) infection: Insights from a work productivity economic model","volume":"60","author":"Younossi","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.clinthera.2015.02.009_bib43","unstructured":"Weisman R. (June 1, 2014). Demand for expensive hepatitis C drug strains insurers: When \u2018miracle\u2019 cures, cost collide. In The Boston Globe. Retrieved on August 18, 2014, from http:\/\/www.bostonglobe.com\/business\/2014\/05\/31\/costly-new-hepatitis-treatments-curing-patients-but-straining-health-care-system-finances\/SmBE9NoUESxjfgphfqvXKL\/story.html."},{"key":"10.1016\/j.clinthera.2015.02.009_bib44","unstructured":"Armstrong D. (January 27, 2014). At $84,000 Gilead Hepatitis C Drug Sets Off Payer Revolt. In Bloomberg News. Retrieved on August 18, 2014, from http:\/\/www.bloomberg.com\/news\/2014-01-27\/at-84-000-gilead-hepatitis-c-drug-sets-off-payer-revolt.html."},{"key":"10.1016\/j.clinthera.2015.02.009_bib45","unstructured":"Centers for Disease Control and Prevention, Division of Viral Hepatitis (June 2010). Hepatitis C General Information. Publication No. 21-1075. Retrieved on August 27, 2014, from http:\/\/www.cdc.gov\/hepatitis\/C\/PatientEduC.htm#cdc."},{"key":"10.1016\/j.clinthera.2015.02.009_bib46","series-title":"Choices in Methods for Economic Evaluation","year":"2012"},{"key":"10.1016\/j.clinthera.2015.02.009_bib47","unstructured":"Process and Methods Guides: Guide to the Methods of Technology Appraisal 2013. National Institute for Health and Care Excellence; 2013. Updated April 4, 2013."},{"key":"10.1016\/j.clinthera.2015.02.009_bib48","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1377\/hlthaff.2014.0005","article-title":"Insurance cancellations in context: stability of coverage in the nongroup market prior to health reform","volume":"33","author":"Sommers","year":"2014","journal-title":"Health Aff (Millwood)"},{"key":"10.1016\/j.clinthera.2015.02.009_bib49","unstructured":"PRNewswire (January 8, 2009). World Health Care Congress and ConnextionsHealth Will Host Leadership Summit to Address Member Retention for Health Insurance Plans. Retrieved on January 6, 2015, from http:\/\/www.thefreelibrary.com\/_\/print\/PrintArticle.aspx?id=191751789."},{"key":"10.1016\/j.clinthera.2015.02.009_bib50","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1093\/cid\/cir076","article-title":"Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: a cure and so much more","volume":"52","author":"Pearlman","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2015.02.009_bib51","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1002\/hep.26481","article-title":"Cognitive improvement after HCV eradication: extending the benefits","volume":"58","author":"Bajaj","year":"2013","journal-title":"Hepatology"},{"issue":"suppl","key":"10.1016\/j.clinthera.2015.02.009_bib52","article-title":"Cerebral MR spectroscopy and patient-reported mental health outcomes in hepatitis C genotype 1 na\u00efve patients treated with ledipasvir and sofosbuvir","volume":"60","author":"Alsop","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.clinthera.2015.02.009_bib53","unstructured":"Centers for Disease Control and Prevention. Testing Recommendations for Hepatitis C Virus Infection. Retrieved on January 5, 2015, from http:\/\/www.cdc.gov\/hepatitis\/hcv\/guidelinesc.htm."},{"key":"10.1016\/j.clinthera.2015.02.009_bib54","unstructured":"Schaeffer S, McCallister E. (September 1, 2014). Back to School Issue: Paying the piper. In BioCentury. Retrieved on September 3, 2014, from http:\/\/www.biocentury.com\/biotech-pharma-news\/coverstory\/2014-09-01\/22nd-biocentury-back-to-school-issue-time-to-try-new-pricing-schemes-a1."},{"key":"10.1016\/j.clinthera.2015.02.009_bib55","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/nbt0614-501","article-title":"Sovaldi makes blockbuster history, ignites drug pricing unrest","volume":"32","author":"Senior","year":"2014","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.clinthera.2015.02.009_bib56","unstructured":"(July 23, 2014). Sovaldi Sales Hit $3.5 Billion in 2Q14. In BioCentury. Retrieved on August 18, 2014, from http:\/\/www.biocentury.com\/dailynews\/topstory\/2014-07-23\/sovaldi-sales-hit-35-billion-in-2q14."},{"issue":"suppl 1","key":"10.1016\/j.clinthera.2015.02.009_bib57","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1093\/cid\/cis393","article-title":"Evolving epidemiology of hepatitis C virus in the United States","volume":"55","author":"Klevens","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2015.02.009_bib58","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1002\/hep.26218","article-title":"Chronic hepatitis C virus (HCV) disease burden and cost in the United States","volume":"57","author":"Razavi","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.clinthera.2015.02.009_bib59","doi-asserted-by":"crossref","first-page":"170","DOI":"10.7326\/M14-0095","article-title":"The changing burden of hepatitis C virus infection in the United States: model-based predictions","volume":"161","author":"Kabiri","year":"2014","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clinthera.2015.02.009_bib60","unstructured":"Decision Resources Group (December 18, 2012). The First Interferon-Free Regimens for Treatment of Hepatitis C Virus are Expected to Launch in 2014 in the United States and Europe and Will Experience Aggressive and Widespread Uptake Through 2021 [press release]. Retrieved on September 21, 2014, from http:\/\/decisionresources.com\/News-and-Events\/Press-Releases\/Hepatitis-C-Virus-121812."},{"key":"10.1016\/j.clinthera.2015.02.009_bib61","unstructured":"Staton T. (April 8, 2014). Express Scripts assembling anti-Sovaldi coalition to shut out Gilead hep C drug. In FiercePharma. Retrieved on August 18, 2014, from http:\/\/www.fiercepharma.com\/story\/express-scripts-assembling-anti-sovaldi-coalition-shut-out-gilead-hep-c-dru\/2014-04-08."},{"key":"10.1016\/j.clinthera.2015.02.009_bib62","unstructured":"BioTrends Research Group (March 19, 2014). Early Uptake by Physicians Establishes Gilead\u2019s Sovaldi as a Defining Hepatitis C Virus Therapy in an Increasingly Competitive Market [press release]. Retrieved on September 8, 2014, from http:\/\/bio-trends.com\/News-and-Events\/Press-Releases\/LaunchTrends-Sovaldi-and-Olysio-US-31914."},{"issue":"RR-4","key":"10.1016\/j.clinthera.2015.02.009_bib63","first-page":"1","article-title":"Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965","volume":"61","author":"Smith","year":"2012","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.clinthera.2015.02.009_bib64","unstructured":"Appleby J. (May 5, 2014). Who Should Get Pricey Hepatitis C Drugs? In Kaiser Health News. Retrieved on September 8, 2014, from http:\/\/kaiserhealthnews.org\/news\/sovaldi-who-should-get-pricey-drug\/."},{"key":"10.1016\/j.clinthera.2015.02.009_bib65","unstructured":"Humer C. (April 17, 2014). UnitedHealth: New Hepatitis C Drug Costs Far More Than Forecast. In Reuters. Retrieved on September 19, 2014, from http:\/\/www.reuters.com\/article\/2014\/04\/17\/us-unitedheal-grp-results-idUSBREA3G0KN20140417."},{"key":"10.1016\/j.clinthera.2015.02.009_bib66","unstructured":"Comer B. (May 21, 2014). Paying for the Future of Medicine. In PharmExecBlog. Retrieved on September 8, 2014, from http:\/\/blog.pharmexec.com\/2014\/05\/21\/paying-for-the-future-of-medicine\/."},{"key":"10.1016\/j.clinthera.2015.02.009_bib67","unstructured":"Millman J. (April 28, 2014). An $84,000 Hepatitis Drug Is Giving States and Insurers a Major Headache. In Washington Post. Retrieved on September 19, 2014, from http:\/\/www.washingtonpost.com\/blogs\/wonkblog\/wp\/2014\/04\/28\/an-84000-hepatitis-drug-is-giving-states-and-insurers-a-major-headache\/."},{"key":"10.1016\/j.clinthera.2015.02.009_bib68","unstructured":"Neuman T, Hoadley J, Cubanski J. (June 5, 2014). The Cost Of A Cure: Medicare\u2019s Role In Treating Hepatitis C. In Health Affairs Blog. Retrieved on August 22, 2014, from http:\/\/healthaffairs.org\/blog\/2014\/06\/05\/the-cost-of-a-cure-medicares-role-in-treating-hepatitis-c\/print\/."},{"key":"10.1016\/j.clinthera.2015.02.009_bib69","unstructured":"Senator Ron Wyden and Senator Chuck Grassley. Letter to John Martin, Chairman & CEO Gilead Sciences, Inc. 11 July 2014. United States Senate Committee on Finance. Retrieved on March 21, 2015, from http:\/\/www.grassley.senate.gov\/news\/news-releases\/senators-seek-details-sovaldi-pricing."},{"key":"10.1016\/j.clinthera.2015.02.009_bib70","unstructured":"Office of the Actuary, US Dept of Health and Human Services (July 30, 2013). Annual Release of Part D National Average Bid Amount and Other Part C & D Bid Related Information. Rockville, Md: DHHS"},{"key":"10.1016\/j.clinthera.2015.02.009_bib71","unstructured":"Office of the Actuary, US Dept of Health and Human Services (July 31, 2014). Annual Release of Part D National Average Bid Amount and Other Part C & D Bid Information. Rockville, Md: DHHS"},{"key":"10.1016\/j.clinthera.2015.02.009_bib72","unstructured":"Armstrong D. (December 10, 2013). Express Scripts Pushes Price Competition for Gilead Drug. In Bloomberg. Retrieved on September 20, 2014, from http:\/\/www.bloomberg.com\/news\/2013-12-10\/express-scripts-pushes-price-competition-for-gilead-drug.html."},{"key":"10.1016\/j.clinthera.2015.02.009_bib73","unstructured":"(April 25, 2014). AbbVie Beats Street, Touches on HCV Pricing. In BioCentury. Retrieved on August 18, 2014, from http:\/\/www.biocentury.com\/dailynews\/financial\/2014-04-25\/abbvie-beats-street-touches-on-hcv-pricing."},{"key":"10.1016\/j.clinthera.2015.02.009_bib74","unstructured":"Staton T. (May 29, 2014). Why Does Gilead\u2019s Sovaldi Cost $84K in the US and $57K in Britain? In FiercePharma. Retrieved on August 18, 2014, from http:\/\/www.fiercepharma.com\/story\/why-does-gileads-sovaldi-cost-84k-us-and-57k-britain\/2014-05-29."},{"key":"10.1016\/j.clinthera.2015.02.009_bib75","unstructured":"Orelli B. (October 9, 2014). Bristol-Myers Co Regroups; Hepatitis C Fight With Gilead Sciences Not Over. In The Motley Fool. Retrieved on October 26, 2014, from http:\/\/www.fool.com\/investing\/general\/2014\/10\/09\/bristol-myers-regroups-hepatitis-c-fight-with-g.aspx."},{"key":"10.1016\/j.clinthera.2015.02.009_bib76","unstructured":"Decision Resources Group (March 19, 2014). Early Uptake by Physicians Establishes Gilead\u2019s Sovaldi as a Defining Hepatitis C Virus Therapy in an Increasingly Competitive Market. Retrieved on September 20, 2014, from http:\/\/www.bio-trends.com\/News-and-Events\/Press-Releases\/LaunchTrends-Sovaldi-and-Olysio-US-31914."},{"key":"10.1016\/j.clinthera.2015.02.009_bib77","unstructured":"Wasserman E. (December 23, 2014). Does the AbbVie-Express Scripts Pact Signal Drug-Price Armageddon? In FiercePharma. Retrieved on December 24, 2014, from http:\/\/www.fiercepharma.com\/story\/does-abbvie-express-scripts-pact-signal-drug-price-armageddon\/2014-12-23."},{"key":"10.1016\/j.clinthera.2015.02.009_bib78","unstructured":"Staton T. (December 22, 2014). Sorry, Gilead. AbbVie Cuts Exclusive Hep C Deal With Express Scripts. In FiercePharma. Retrieved on December 24, 2014, from http:\/\/www.fiercepharma.com\/story\/sorry-gilead-abbvie-cuts-exclusive-hep-c-deal-express-scripts\/2014-12-22."},{"key":"10.1016\/j.clinthera.2015.02.009_bib79","unstructured":"Wasserman E. (October 29, 2014). Gilead Misses the Mark in Q3 Due to Obamacare Fee and Dip in Sovaldi Revenue. In FiercePharma. Retrieved on December 24, 2014, from http:\/\/www.fiercepharma.com\/story\/gilead-misses-mark-q3-due-obamacare-fee-and-dip-sovaldi-revenue\/2014-10-29."},{"key":"10.1016\/j.clinthera.2015.02.009_bib80","unstructured":"Staton T. (December 24, 2014). Get Ready To Negotiate Drugmakers: Payers Are Armed for Drug-Pricing Battle. In FiercePharma. Retrieved on December 24, 2014, from http:\/\/www.fiercepharma.com\/story\/get-ready-negotiate-drugmakers-payers-are-armed-drug-pricing-battle\/2014-12-24."},{"key":"10.1016\/j.clinthera.2015.02.009_bib81","unstructured":"Staton T. (November 20, 2014). France Strikes Big Hep C Treatment Deal for Gilead\u2019s Sovaldi. Retrieved on December 24, 2014, from http:\/\/www.fiercepharma.com\/story\/france-strikes-big-hep-c-treatment-deal-gileads-sovaldi\/2014-11-20."},{"key":"10.1016\/j.clinthera.2015.02.009_bib82","unstructured":"Bekrot B, Humer C. (January 5, 2014). UPDATE 1-CVS to cover Gilead hepatitis C treatment over AbbVie regimen. Retrieved on March 8, 2015, from http:\/\/www.reuters.com\/article\/2015\/01\/05\/gilead-cvs-idUSL1N0UK1B920150105."},{"key":"10.1016\/j.clinthera.2015.02.009_bib83","unstructured":"Langreth R. (January 8, 2015). Gilead Strikes Hepatitis C Deal With Anthem. Retrieved on March 8, 2015, from http:\/\/www.bloomberg.com\/news\/articles\/2015-01-08\/gilead-strikes-hepatitis-c-deal-with-anthem."},{"key":"10.1016\/j.clinthera.2015.02.009_bib84","unstructured":"Wasserman E. (January 16, 2015). Gilead blazes ahead in hep C pricing battle with two new PBM deals. Retrieved on March 8, 2015, from http:\/\/www.fiercepharma.com\/story\/gilead-blazes-ahead-hep-c-pricing-battle-two-new-pbm-deals\/2015-01-16."},{"key":"10.1016\/j.clinthera.2015.02.009_bib85","unstructured":"Wasserman E. (January 29, 2015). Gilead zooms past AbbVie in hep C race with UnitedHealth deal. Retrieved on March 8, 2015, from http:\/\/www.fiercepharma.com\/story\/gilead-zooms-past-abbvie-hep-c-race-unitedhealth-deal\/2015-01-29."},{"key":"10.1016\/j.clinthera.2015.02.009_bib86","unstructured":"Pollack A. (February 3, 2015). Sales of Sovaldi, New Gilead Hepatitis C Drug, Soar to $10.3 Billion. Retrieved on March 8, 2015, from http:\/\/www.nytimes.com\/2015\/02\/04\/business\/sales-of-sovaldi-new-gilead-hepatitis-c-drug-soar-to-10-3-billion.html."},{"key":"10.1016\/j.clinthera.2015.02.009_bib87","unstructured":"Lawitz E, Poordad F, Gutierrez JA, et al. C-SWIFT: Grazoprevir (MK-5172) + Elbasvir (MK-8742) + sofosbuvir in Treatment-Naive Patients With Hepatitis C Virus Genotype 1 Infection, With and Without Cirrhosis, for Durations of 4, 6, or 8 Weeks (Interim Results). Conference Reports for NATAP. Retrieved on January 3, 2015, from http:\/\/www.natap.org\/2014\/AASLD\/AASLD_11.htm."},{"key":"10.1016\/j.clinthera.2015.02.009_bib88","unstructured":"Bristol-Myers Squibb. Phase III Daclatasvir and sofosbuvir for Genotype 3 Chronic HCV (ALLY 3). In clinicaltrials.gov. Retrieved on September 8, 2014, from http:\/\/clinicaltrials.gov\/show\/NCT02032901. NLM Identifier NCT02032901."},{"issue":"suppl","key":"10.1016\/j.clinthera.2015.02.009_bib89","article-title":"Interferon-free regimens of ombitasvir and ABT-450\/r with or without ribavirin in patients with HCV genotype4 infection: PEARL-I study results","volume":"60","author":"Pol","year":"2014","journal-title":"Hepatology"},{"issue":"suppl","key":"10.1016\/j.clinthera.2015.02.009_bib90","article-title":"Ledipasvir\/sofosbuvir with ribavirin for the treatment of HCV in patients with decompensated cirrhosis: preliminary results of a prospective, multicenter study","volume":"60","author":"Flamm","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.clinthera.2015.02.009_bib91","unstructured":"Keshavan M. (August 30, 2014). Novartis\u2019 next blockbuster? New drug cuts heart failure death rate a stunning 20 percent. In MedCityNews. Retrieved on September 21, 2014, from http:\/\/medcitynews.com\/2014\/08\/novartis-next-blockbuster-new-drug-cuts-heart-failure-death-rate-stunning-20-percent\/."},{"key":"10.1016\/j.clinthera.2015.02.009_bib92","unstructured":"The Associated Press (September 1, 2014). First-of-a-Kind Novartis Heart Failure Drug Saves Lives, Cuts Hospitalizations: Study. In NY Daily News. Retrieved on September 21, 2014, from http:\/\/www.nydailynews.com\/life-style\/health\/novartis-heart-failure-drug-saves-lives-cuts-hospitalizations-study-article-1.1923842."},{"key":"10.1016\/j.clinthera.2015.02.009_bib93","unstructured":"Novartis International AG (November 28, 2014). Novartis\u2019 Heart Failure Medicine LCZ696 Granted Accelerated Assessment by CHMP in Europe. Retrieved on December 31, 2014, from http:\/\/www.novartis.com\/newsroom\/media-releases\/en\/2014\/1874782.shtml."}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291815000752?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291815000752?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,31]],"date-time":"2020-08-31T14:07:25Z","timestamp":1598882845000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291815000752"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5]]},"references-count":93,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["S0149291815000752"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2015.02.009","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2015,5]]}}}